The "Ozempic Baby" Phenomenon: GLP-1 Medications and Fertility

Social media calls them "Ozempic babies" — unplanned pregnancies in people taking GLP-1 medications who had previously struggled to conceive, sometimes for years. The trend has sparked both excitement and concern. Here's what the evidence actually shows.

Why weight loss improves fertility

The link between obesity and reduced fertility is well-established. Excess adipose tissue produces estrone (a form of estrogen), which disrupts the hypothalamic-pituitary-ovarian axis — the hormonal feedback loop that governs ovulation. In practical terms:

• Women with BMI ≥30 are 3x more likely to experience anovulation (failure to ovulate)
• Even a 5-10% weight loss can restore regular ovulation in many women with obesity-related infertility
• GLP-1 medications produce 15-22% weight loss on average — far exceeding this threshold

The PCOS connection

An estimated 50-80% of women with polycystic ovary syndrome (PCOS) are overweight or obese. PCOS is the leading cause of anovulatory infertility, and its symptoms — irregular cycles, excess androgens, insulin resistance — are significantly improved by weight loss.

A 2025 retrospective study in Fertility and Sterility found that women with PCOS who lost ≥15% body weight on semaglutide had:

• 87% resumption of regular menstrual cycles (vs. 35% with lifestyle intervention alone)
• 62% spontaneous ovulation confirmed by progesterone levels
• Significant reductions in free testosterone and DHEA-S

Oral contraceptive warning

There's an important pharmacological interaction: GLP-1 medications slow gastric emptying, which can reduce the absorption of oral medications — including birth control pills. The FDA label for semaglutide notes that patients should use a backup contraceptive method (barrier method) for 4 weeks after initiating treatment and after each dose increase.

This is likely contributing to unplanned pregnancies attributed to "Ozempic babies." The medication didn't cause fertility — it restored it by reducing weight, while simultaneously reducing the effectiveness of oral contraception.

Planning pregnancy on GLP-1s

Current FDA guidance is clear: GLP-1 medications should be discontinued at least 2 months before a planned pregnancy. The medications are Category X in pregnancy (animal studies showed fetal harm).

If you're considering pregnancy while on GLP-1 treatment:

• Discuss timeline with your prescribing physician
• Plan a 2-month washout period before attempting conception
• Switch to non-oral contraception during treatment if needed
• Continue folic acid supplementation throughout

For men

Male obesity is also associated with reduced fertility — lower testosterone, decreased sperm quality, and erectile dysfunction. Preliminary data suggests GLP-1-mediated weight loss improves all three parameters, though large-scale studies specific to male fertility are still underway.

Reviewed by Dr. Rachel Morrison, MD, ABOM. Updated July 2026. If you are pregnant or planning pregnancy, consult your OB/GYN before making any changes to your medication regimen.